Skip to main content

Table 3 Outcomes of thiopurine therapy in patients with or without NUDT15 polymorphisms

From: TPMT and NUDT15 polymorphisms in thiopurine induced leucopenia in inflammatory bowel disease: a prospective study from India

 

NUDT15 (mutated)

(N = 13)

n (%)/ Median (IQR)

Wild Genotype

(N = 102)

n (%)/ Median (IQR)

p value

Hemoglobin (g/dL) at end of follow up

12 (2.8)

11.05 (3.4)

0.289

Total leucocyte count (× 106/L) at end of follow up

3600 (1700)

5700 (3575)

0.006

Platelet count (× 106/L) at end of follow up

214,000 (109,000)

254,000 (132,500)

0.289

Duration of thiopurine use (months)

11 (9)

8 (15.25)

0.168

Max tolerated azathioprine equivalent dose (mg/d)

50 (50)

100 (25)

0.253

Leukopenia

7 (53.8%)

25 (24.5%)

0.026

Idiosyncratic reaction

0

6 (5.9%)

1.000

Treatment interruption

7 (53.8%)

29 (28.4%)

0.063

  1. Bold means statistically significant